TrialSignal
Clinical trial intelligence report
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Pharmacokinetics of MK-1942 Administered to Alzheimer's Disease Patients Receiving Donepezil Treatment.
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT04308304-Jul 28, 2026
NCT ID
NCT04308304
Status
COMPLETED
Phase
PHASE1
Sponsor
Merck Sharp & Dohme LLC
Executive brief
Investment-Ready Snapshot
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Pharmacokinetics of MK-1942 Administered to Alzheimer's Disease Patients Receiving Donepezil Treatment. is a PHASE1 clinical asset sponsored by Merck Sharp & Dohme LLC in Alzheimer's Disease. SEO and diligence focus: MK-1942, Donepezil, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT04308304
Indication
Alzheimer's Disease
Modality
small molecule
Target
MK-1942, Donepezil, Placebo
Intervention
MK-1942, Donepezil, Placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.